|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 34.40 USD | -1.19% |
|
+14.40% | - |
| 10-15 | JPMorgan Initiates Hemab Therapeutics at Overweight With $70 Price Target | MT |
| 09-24 | Hemab Therapeutics Holdings, Inc. Announces Board and Committee Changes, Effective September 24, 2026 | CI |
Chart: Technical Analysis
NasdaqUSD
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| COAG | Delayed | |
CBOE
| COAG | Real-time |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Neutral | Neutral |
| Resistance | 41.22 | 54.94 | 54.94 |
| Spread/Res. | -16.55% | -37.39% | -37.39% |
| Spread/Supp. | +21.25% | +37.71% | +37.71% |
| Support | 28.37 | 24.98 | 24.98 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- COAG Stock
- Charts Hemab Therapeutics Holdings, Inc.
Select your edition
All financial news and data tailored to specific country editions
